Recently, the European Molecular Genetics Quality Network (EMQN) released its 2019 BRCA Ovarian (Germline) competency assessment report, and Annoroad once again passed the quality evaluation with full marks, proving its standardization and accuracy of each branch from gene detection to clinical annotation with strength.